Phase 3 trial of leniolisib in activated PI3Kδ syndrome, dabrafenib plus trametinib in relapsed/refractory hairy cell leukemia, and TγδLGL leukemia as a more symptomatic subset of leukemia
Blood Podcast
00:00
T-Gamma-Delta-LGL Patients Show Lower Survival Rates Compared to T-Alpha Beta LGL Patients
T-gamma-delta-LGL cases were more frequently symptomatic, with reduced overall survival compared to T-alpha beta-LGL. The study by Berea suggests that treatment selection needs to be based on the subtype of LGL. Until now, low-dose methotrexate or cyclophosphamide have been used as first-line therapy independent of the LGL variant.
Transcript
Play full episode
